Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector)

Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor)

Aranesp (Darbepoetin) – EU: ECJ says ‘no’ to Kirin Amgen, ‘yes’ to Member States’ transitional discretion: Case C-66/09 Kirin Amgen Inc v Lietuvos Respublikos valstybinis patentų biuras, Amgen Europe BV (The SPC Blog)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

WSJ mixing up issues in access to drugs debate? (Spicy IP)

Evergreen or nevergreen: that is the question – Coversyl (Perindopril); Diovan (Valsartan) (IPKat)

Australia: Senate enquiry into gene patents put on hold (Patentology)

Australia: Gene patents feature on Australian ‘Four Corners’ tv program (Patentology) (Patentology)

China: The basics on China Pharma, Part 3: Mistakes to be avoided (China Law Blog)

India: NCE’s outside the scope of Sec. 3(d), efficacy data not required (Patent Circle)

India: WSJ criticises DCGI report on spurious drugs in India (Spicy IP)

US: CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector)

US: Citing possible bias, ACLU asks Rader to recuse himself in Myriad case: Association of Molecular Pathology et. al. v. U.S. Patent and Trademark Office et. al, (Prior Art)

US: District Court New Jersey: Drug label may provide evidence of intent to induce infringement even though required by the FDA: Hoffmann-La Roche Inc. v. Genpharm Inc. et al. (Docket Report)

US: Helicos Biosciences Corp files patent infringement suit against Pacific Biosciences of California in response to its manufacture and use of Single Molecule Real Time DNA sequencing technology (Patent Docs)

US: Report predicts tough road ahead for some generics after Federal Circuit patent use code decisions (FDA Law Blog)

Products

Angiomax (Bivalirudin) – US: APP moves forward with appeal notice in Angiomax PTE litigation in light of PTO/FDA indecision: Medicines Company v Kappos (FDA Law Blog)

Aranesp (Darbepoetin) – EU: ECJ says ‘no’ to Kirin Amgen, ‘yes’ to Member States’ transitional discretion: Case C-66/09 Kirin Amgen Inc v Lietuvos Respublikos valstybinis patentų biuras, Amgen Europe BV (The SPC Blog)

Aricept (Donepezil) – US: District Court denies Apotex declaratory judgment motion on generic Aricept; does not accept ‘prompt launch’ and ‘indefinite delay’ jurisdiction theories (FDA Law Blog)

Chantix (Varenicline) – US: Pfizer files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (AboutLawsuits.com)

Copaxone (Glatiramer) – US: Court denies Sandoz/Momenta’s summary judgment of invalidity in Copaxone litigation (SmartBrief)

Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor)

Gemzar (Gemcitabine) – US: Sun Pharmaceuticals v Eli Lilly: The creeping expansion of the doctrine of obviousness-type double patenting (Holman’s Biotech IP Blog)

Levonorgestrel – India: Cipla prevails in post grant opposition proceeding against Richter Gedeon (Generic Pharmaceuticals and IP)

Lovenox (Enoxaparin) – US: Sanofi denied preliminary injunction against FDA regarding approval of Sandoz’s generic Lovenox (Patent Docs)

Lunesta (Eszopiclone) – US: Sepracor settles with Wockhardt in Lunesta patent suit (Patent Docs)

Mucinex (Guaifenesin) – US: What’s an equivalent?- CAFC vacates and remands in Adams Respiratory v. Perrigo Co (IPBiz)

Norvir (Ritonavir) – US: Abbott’s HIV/AIDS drug patents challenged by PUBPAT (IP Watchdog)

ReFacto (Moroctocog) and Xyntha (Antihemophilic factor) – US: Novartis drops one of three patents from ReFacto/Xyntha suit against Wyeth (Patent Docs)

Strattera (Atomoxetine) – US: CAFC grants injunction pending disposition of Lilly v Actavis Elizabeth (Patent Docs)

Valcyte (Valganciclovir) – US: Ranbaxy settles patent dispute with Roche over Valcyte (Patent Docs)